{"id":216,"date":"2020-04-03T08:57:40","date_gmt":"2020-04-03T12:57:40","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=216"},"modified":"2020-04-03T08:57:40","modified_gmt":"2020-04-03T12:57:40","slug":"covid-19-treatment-approvals-accelerated-by-new-fda-ctap-program","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/04\/03\/covid-19-treatment-approvals-accelerated-by-new-fda-ctap-program\/","title":{"rendered":"COVID-19 Treatment Approvals Accelerated by New FDA CTAP Program"},"content":{"rendered":"<p>On March 31, 2020, the U.S. Food &amp; Drug Administration (FDA)\u00a0<a title=\"Coronavirus Treatment Acceleration Program (CTAP)\" href=\"https:\/\/www.fda.gov\/drugs\/coronavirus-covid-19-drugs\/coronavirus-treatment-acceleration-program-ctap\" target=\"_blank\" rel=\"noopener noreferrer\">introduced<\/a>\u00a0a specially designed \u201cemergency program\u201d\u2014dubbed the Coronavirus Treatment Acceleration Program (CTAP)\u2014to provide patients with faster access to new COVID-19 treatments. The CTAP allows FDA to \u201cmove new therapies to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful.\u201d<\/p>\n<p>Given the rapidly increasing rate of COVID-19 confirmed cases and fatalities in the United States, efforts to streamline FDA processes may prove crucial to uncovering and delivering viable treatments.<\/p>\n<p>To read the full text of this Duane Morris\u00a0<em>Alert<\/em>, please\u00a0<a href=\"https:\/\/www.duanemorris.com\/alerts\/fda_unveils_program_expedite_coronavirus_treatments_0420.html\" target=\"_blank\" rel=\"noopener noreferrer\">visit the firm website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On March 31, 2020, the U.S. Food &amp; Drug Administration (FDA)\u00a0introduced\u00a0a specially designed \u201cemergency program\u201d\u2014dubbed the Coronavirus Treatment Acceleration Program (CTAP)\u2014to provide patients with faster access to new COVID-19 treatments. The CTAP allows FDA to \u201cmove new therapies to patients as quickly as possible, while at the same time finding out whether they are helpful &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/04\/03\/covid-19-treatment-approvals-accelerated-by-new-fda-ctap-program\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;COVID-19 Treatment Approvals Accelerated by New FDA CTAP Program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[161,429,29,209,388,298,402],"ppma_author":[521],"class_list":["post-216","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-accelerated-market-entry","tag-covid-19","tag-fda","tag-frederick-ball","tag-justin-stern","tag-patrick-gallagher","tag-sandra-stoneman"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","author_category":"1","last_name":"Sullivan","first_name":"Margaret","job_title":"","user_url":"http:\/\/www.duanemorris.com","description":"<a href=\"http:\/\/www.duanemorris.com\">Visit the Duane Morris website.<\/a>"}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=216"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/216\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=216"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}